anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A cosmetic composition containing a bacteriocin(Lactobiocin) produced by Lactococcus sp. HY 49 is provided. Therefore, the cosmetic composition inhibits the growth of microorganisms which reside on the skin and induce skin inflammation and acne, and has extended storage. CONSTITUTION: A cosmetic composition for prevention of acne and inflammation contains a bacteriocin culture liquid(Lactobiocin) produced by Lactococcus sp. HY 49(KFCC-10842) in an amount of 0.01 to 10% by weight, based on the total weight of the composition. The bacteriocin is prepared by inoculating and culturing Lactococcus sp. HY 49 cells, centrifuging the culture liquid, followed by adding propanol and sodium chloride to the supernatant and centrifuging it to obtain precipitate, dissolving the precipitate in a citrate buffer solution and dialyzing it. The bacteriocin shows a relatively broad range of antibacterial activity and is stable in an organic solvent and a detergent.
The ketone mono ester is commercially available dietary supplement beverage named "H.V.M.N. Ketone Ester", marketed by HVMN Inc®. The KME beverage consists of water, D-β-hydroxybutyrate ester, stevia leaf extract, natural flavors, malic acid, potassium sorbate and potassium benzoate. The active ingredient is the D-β-hydroxybutyrate ester, with each dose containing 25g. Participants will be asked to ingest this 5 times daily for 3 days (72 hours), to a total of 15 doses during the study.
Group 3: will include 36 patients with multiple common, plantar and/or plane warts. They will receive cryotherapy sessions every two weeks until complete clearance or for a maximum of 6 sessions.
All subjects will be treated using IMRT with the standard fractionation for T1a glottic cancer at Fox Chase Cancer Center: 63 Gy in 28 fractions; 6 for T1a and 65.25 Gy in 29 fractions; 33 for T2a. Treatment will be followed by functional assessments performed at months 1,3,6,12,and 24.
Lipopolysaccharide (LPS) can induce systemic inflammatory response (SIR) in animals. Understanding the regulatory mechanism of SIR and therapies to ensure healthy growth is urgently needed. Chromatin remodeling plays a crucial role in the expression of genes involved in immune diseases. In the present study, the ATAC-seq analysis revealed 3491 differential open chromatin sites in the spleen of chicks with SIR induced by LPS challenge, and we presented the motifs on these sites and the associated transcription factors. The regulatory network was presented by combining the differential open chromatin data with the mRNAs and exploded cytokines. Interestingly, the LPS challenge could regulate the mRNA expression of 202 genes through chromatin reprogramming, including critical genes such as TLE1 and JUN, which regulate signaling pathways such as I-κB kinase/NF-κB, Toll-like receptor, and downstream cytokine genes. Furthermore, dietary daidzein could inhibit DNA topoisomerase II, which reprograms the spatial conformation of chromatin in the inflammatory response and attenuates SIR. In conclusion, we successfully identified key genes directly regulated by chromatin reprogramming in SIR and demonstrated the chromatin epigenome signatures and transcriptional regulatory network, which provides an important reference for further research on avian epigenetics. There is great potential for alleviating SIR using dietary daidzein.
Revascularization of ischemic myocardium following cardiac damage is an important step in cardiac regeneration. However, the mechanism of arteriogenesis has not been well described during cardiac regeneration. Here we investigated coronary artery remodeling and collateral growth during cardiac regeneration. Neonatal MI was induced by ligature of the left descending artery (LAD) in postnatal day (P) 1 or P7 pups from the Cx40-GFP mouse line and the arterial tree was reconstructed in 3D from images of cleared hearts collected at 1, 2, 4, 7 and 14 days after infarction. We show a rapid remodeling of the left coronary arterial tree induced by neonatal MI and the formation of numerous collateral arteries, which are transient in regenerating hearts after MI at P1 and persistent in non-regenerating hearts after MI at P7. This difference is accompanied by restoration of a perfused or a non-perfused LAD following MI at P1 or P7 respectively. Interestingly, collaterals ameliorate cardiac perfusion and drive LAD repair, and lineage tracing analysis demonstrates that the restoration of the LAD occurs by remodeling of pre-existing arterial cells independently of whether they originate in large arteries or arterioles. These results demonstrate that the restoration of the LAD artery during cardiac regeneration occurs by pruning as the rapidly forming collaterals that support perfusion of the disconnected lower LAD subsequently disappear on restoration of a unique LAD. These results highlight a rapid phase of arterial remodeling that plays an important role in vascular repair during cardiac regeneration.
Aim: Anthracycline induced cardiotoxicity is the most common constrains of its use in treatment of various types of cancer. This study aimed to investigate benefits from adding L-carnitine and Silymarin compared to anthracycline chemotherapy alone in patients with cancer.

Methods: 83 patients were recruited from Clinical Oncology Department, Tanta University, Egypt, then prospectively randomized to receive their anthracycline containing therapeutic regimen, control group (n=33) or anthracycline plus L-carnitine, L-carnitine group (n=25), or anthracycline plus Silymarin, Silymarin group (n= 25). Blood samples were collected at begging and after 6 months to measure LDH, CK-MB, cTn I, Anticardiolipin IgG, Fe, ferritin and TIBC and % of saturation. % EF was documented. Data were statistically analyzed by ANOVA and paired t test. P \<0.05 was statistically significant.
Bone cancer pain (BCP) is a complex clinical challenge, with current treatments often falling short of providing adequate relief. Remimazolam, a benzodiazepine receptor agonist recognized for its anxiolytic effects, has emerged as a potential agent in managing BCP. This study explores the analgesic properties of remimazolam and its interaction with the translocator protein (TSPO), previously known as the peripheral benzodiazepine receptor, in spinal astrocytes. In the context of BCP, previous research has indicated that TSPO expression in spinal astrocytes may serve a protective regulatory function in neuropathic pain models. Building on this, the BCP mice received various doses of remimazolam on the 15th day post-inoculation, and pain behavior was assessed over time. The results showed that BCP induced an upregulation of TSPO and astrocyte activation in the spinal dorsal horn, alongside increased extracellular signal-regulated kinase (ERK) signaling and inflammatory cytokine expression. Remimazolam administration resulted in a dose-dependent reduction of pain behaviors, which corresponded with a decrease in both ERK pathway activation and inflammatory factor expression. This suggests that remimazolam's analgesic effects are mediated through its action as a TSPO agonist, leading to the attenuation of neuroinflammation and pain signaling pathways. Importantly, the analgesic effects of remimazolam were reversed by the TSPO antagonist PK11195, underscoring the pivotal role of TSPO in the drug's mechanism of action. This reversal also reinstated the heightened levels of ERK activity and inflammatory mediators, further confirming the involvement of TSPO in the modulation of these pain-related processes. These findings open new avenues for the therapeutic management of bone cancer pain, positioning remimazolam as a promising candidate for further investigation and development.
PURPOSE:To obtain pasting agent having excellent pasting property to skin and good balance of adhesive property and cohesive property comprising an adhesive mass layer of (meth)acrylate polymer containing abundant dissolved drug and exhibiting high releasability and a backing supporter layer. CONSTITUTION:Reinforcing non-fibrous filler (e.g. fine powdered silica) and a drug are contained in (meth)acrylate polymer having a glass transition temperature (Tg) below -71 deg.C as an adhesive mass. Then, an age resistor and stabilizer, etc., are added to said composition, as necessary, to obtain an adhesive mass layer. Thus, a backing supporter layer composed of supporter such as nonwoven cloth and said adhesive mass layer are used as principal components and releasability-protecting paper or sheet is adhered on the surface of said adhesive mass layer to afford the aimed article. Besides, value of holding force (H) and value of adhesive force (F) of said adhesive mass layer satisfy the relation of H/F>0.3(sec/g) and F>200(g).
Levocarnitine is a carrier molecule in the transport of long-chain fatty acids across the inner mitochondrial membrane.

The chemical name of levocarnitine is 3-carboxy-2(R)-hydroxy-N,N,N-trimethyl-1-propanaminium, inner salt. Levocarnitine is a white crystalline, hygroscopic powder. It is readily soluble in water, hot alcohol, and insoluble in acetone. The specific rotation of levocarnitine is between –29° and –32°. Its chemical structure is:

Levocarnitine injection, USP is a sterile aqueous solution containing 1 g of levocarnitine per 5 mL vial, and 4 g of levocarnitine per 20 mL vial, and water for injection q.s. The pH is adjusted to 6 to 6.5 with hydrochloric acid or sodium hydroxide.
A computer-implemented method for providing a vascular image data record includes receiving a plurality of projection-X-ray images recorded in temporal succession. The plurality of projection-X-ray images at least partially map a common examination region of an examination object. The plurality of projection-X-ray images map a temporal change in the examination region of the examination object. A change image data record is determined in each case based on at least one region of interest of the plurality of projection-X-ray images. The at least one region of interest includes a plurality of image points. The change image data record in each case includes a time-intensity curve for each of the image points. The vascular image data record is generated based on the change image data record, and the vascular image data record is provided.
They were treated with phototherapy including 308-nm excimer laser or narrowband ultraviolet B (NB-UVB). They had vitamin D supplementation through the injection of cholecalciferol additionally. The study group with vitamin D deficiency was treated with intramuscular injection of 200,000 IU cholecalciferol (Kwangdong Pharmaceutical Co., Seoul, Korea) once at baseline. Total study period was 6 months and the clinical assessments with checking adverse events were conducted every month.
A polymeric prodrug is described which comprises at least one polymer attached via at least one permanent bond to a bicine linker. The bicine linker is attached via a temporary linkage to an amine containing biologically active moiety. The amine containing biologically active moiety - such as a drug - can be released by cleaving the temporary linkage. In one example, the prodrug of or corresponding polymeric prodrug linker reagent has the following structure:  (formula Ia)in which T is D or A (D being a residue of an amine containing biologically active moiety and A being a leaving group). X is a spacer moiety such as R13-Y1. Y1 is O, S, NR6, succinimide, maleimide, unsaturated carbon-carbon bonds or any heteratom containing a free electron pair or is absent. Rl 3 is selected from substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryls, substituted aryls, substituted or non-substituted heteroaryls. R2 and R3 are selected independently from hydrogen, acyl groups, or protecting groups for hydroxyl groups. R4 to R12 are selected independently from hydrogen, X-Rl, substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryls, substituted aryls, substituted or non-substituted heteroaryls, cyano, nitro, halogen, carboxy, carboxamide. R1 is a polymer. In other examples the polymer Rl is placed at other positions.
A designated trained auriculotherapy provider will place gold beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
Glucose deprivation is an attractive strategy in cancer research and treatment. Cancer cells upregulate glucose uptake and metabolism for maintaining accelerated growth and proliferation rates. Specifically blocking these processes is likely to provide new insights to the role of glucose transport and metabolism in tumorigenesis, as well as in apoptosis. As solid tumors outgrow the surrounding vasculature, they encounter microenvironments with a limited supply of nutrients leading to a glucose deprived environment in some regions of the tumor. Cancer cells living in the glucose deprived environment undergo changes to prevent glucose deprivation-induced apoptosis. Knowing how cancer cells evade apoptosis induction is also likely to yield valuable information and knowledge of how to overcome the resistance to apoptosis induction in cancer cells. Disclosed herein are novel anticancer compounds that inhibit basal glucose transport, resulting in tumor suppression and new methods for the study of glucose deprivation in animal cancer research.
FIELD: pharmaceutics. SUBSTANCE: pharmaceutical composition is designed in the form of membrane-covered center. The latter contains efficient quantity of indapamide as active substance. As pharmaceutically acceptable target additives the center contains, weight portion/1 weight portion indapamide: polyvinylpyrrolidone at average mol. wt. being above 19000, 0.3-2.4; saccharide, 15.0-33.0; starch, 4.2- 12.0; sodiumdodecylsulfate, 0.001-0.5; stearic acid and/or its salt and/or talc, 0.1-2.1. Preferably, the center includes pressed powdered granules. Method to obtain pharmaceutical composition includes wet granulating the mixture of indapamide with saccharide, starch, polyvinylpyrrolidone, sodiumdodecylsulfate and, not obligatory, talc, followed by drying, addition of powdering agent, formation of the mixture into the center and application of membrane onto centers obtained. Said composition has got resistance at keeping and storage terms above 2 years, is easily decomposed that provides high degree of indapamide releasing. Sequence in operations conducted and technological parameters of the present method provide manufacturing medicinal form of satisfactory strength. EFFECT: improved results. 14 cl, 4 ex
All participants received L-carnitine supplementation (500 mg per tablet per day, provided by GNC) for one month. Oral carnitine challenge tests and fecal sampling were conducted both before and after the intervention.
Medicaments containing a total extract of Piper methysticum (kava-kava) are new. The medicaments may be prepd. in the form of capsules, tablets or degrees contg. 10-50 mg, pref. 30 mg of the extract. Such medicaments are given, 2-4 times daily then, when the blood pressure has returned to normal, 1-2 times daily. The dosage may be later decreased further, whilst keeping the blood pressure normal. Medicaments are very effective at low dosages and free from side effects.
The classical amyloid cascade hypothesis postulates that the aggregation of amyloid plaques and the accumulation of intracellular hyperphosphorylated Tau tangles, together, lead to profound neuronal death. However, emerging research has demonstrated that soluble amyloid-β oligomers (SAβOs) accumulate early, prior to amyloid plaque formation. SAβOs induce memory impairment and disrupt cognitive function independent of amyloid-β plaques, and even in the absence of plaque formation. This work describes the development and characterization of a novel anti-SAβO (E3) nanobody generated from an alpaca immunized with SAβO. In-vitro assays and in-vivo studies using 5XFAD mice indicate that the fluorescein (FAM)-labeled E3 nanobody recognizes both SAβOs and amyloid-β plaques. The E3 nanobody traverses across the blood-brain barrier and binds to amyloid species in the brain of 5XFAD mice. Imaging of mouse brains reveals that SAβO and amyloid-β plaques are not only different in size, shape, and morphology, but also have a distinct spatial distribution in the brain. SAβOs are associated with neurons, while amyloid plaques reside in the extracellular matrix. The results of this study demonstrate that the SAβO nanobody can serve as a diagnostic agent with potential theragnostic applications in Alzheimer's disease.
264 patients scheduled for an inguinal hernia repair using one of three procedures (Lichtenstein, Barwell and TEP = total extraperitoneal hernioplasty) are being randomly allocated intra-operatively into two groups. Group I patients receive a local injection of 20ml Carbostesin® 0.25% at the end of the operation according to a standardised procedure. Group II patients get a 20 ml placebo (0.9% Saline) injection. We use pre-filled identically looking syringes for blinded injection, i.e. the patient, the surgeon and the examinator who performs the postoperative clinical follow-ups remain unaware of group allocation. The primary outcome of the study is the occurrence of developing chronic pain (defined as persistent pain at 3 months FU) measured by VAS and Pain Matcher® device (Cefar Medical AB, Lund, Sweden).

In addition to a sample size re-evaluation three interim analyses are planned after 120, 180 and 240 patients had finished their 3-months follow-up to allow for early study termination.
Health literacy plays a crucial role in promoting and maintaining the health of patients with chronic illnesses. Therefore, adequate assessments and the application of interventions based on people's health literacy strengths, needs, and preferences are required to improve health outcomes. This study aimed to evaluate the psychometrical properties of the Health Literacy Questionnaire (HLQ) in Koreans with chronic diseases. Data were collected from 278 patients (57.04±15.22 years) diagnosed with chronic disease, including kidney disease, hypertension, and diabetes, who visited the outpatient clinic of a university hospital from June to December 2020. For validity assessment, construct, convergent, and discriminant validities were evaluated, along with the HLQ reliability using Cronbach's α. One-way analysis of variance was used to evaluate mean differences in the HLQ scale scores based on patients' characteristics. The confirmatory factor analysis (CFA) indicated that all items were loaded on their respective factors. The model fit of a full nine-factor CFA model showed satisfactory or better fit compared with nine one-factor CFA model; χ2WLSMV (866) = 576.596 (p < .001), comparative normed fit index of 1.000 (reference: >0.950), Tucker-Lewis index of 0.981 (reference: >0.950), root mean square error of approximation of 0.066 (reference: <0.080), and standardized root mean square residual of 0.055 (reference: <0.080). All scales demonstrated good to excellent internal consistency (Cronbach's α ≥.757). Sociodemographic characteristic variables with significant score differences in HLQ scores were reported across nine scales, with the level of education and income showing significant score differences in 8 and 6 scales, respectively. This study revealed that the Korean version of the HLQ has many strong measurement properties among patients with chronic diseases. The validation indicated the HLQ as a robust tool that is used cross-culturally and is recommended for use in the Korean population.
PROBLEM TO BE SOLVED: To obtain the subject compound useful as an intermediate of a medicinal compound in a good efficiency and a large amount by reacting a halogen substituted phenyl derivative with a disulfide derivative in the presence of a metal catalyst. SOLUTION: This dibenzo[b,f]thiepin derivative is obtained by a known method from a diaryl sulfide derivative of formula III, which is obtained by reacting a halogen substituted phenyl derivative expressed by formula I (X is a halogen; R1 to R5 are each H, a lower alkyl, an aryl, etc.), with a disulfide derivative expressed by formula II (R6 to R10 are each a lower alkyl, an aryl, etc.), in the presence of a metal catalyst (preferably a copper catalyst or a nickel catalyst) preferably using a solvent (e.g.; dimethylformamide or dimethyl sulfoxide) at 80-210 deg.C for 1-5 hr for forming a sulfide bond. The compound of the formula III can be purified e. g. by a neutralization, filtration, extraction, washing, etc. The compound of the formula II is obtained preferably by oxidizing a thiol derivative expressed by formula IV as a raw material.
PURPOSE: To obtain an arterialization inhibitor containing a specific compound as an active ingredient, excellent in arterialization-inhibiting action, having low toxicity and capable of safely using and useful for preventing and treating diabetic retinopathy, chronic inflammation, psoriasis and arteriosclerosis. CONSTITUTION: This inhibitor contains 3-hydroxymethyl-6-methoxy-8-hydroxy-1 H-2-benzopyran-1-one of the formula as an active ingredient. The compound of the formula is obtained by culturing, e.g. Streptoverticillium eurocidicum M-143-37Fl1 strain (FERM-BP-2783) and collecting the compound from the culture solution. The content of the compound of the formula is preferably 5-50wt.% based on the total composition when the inhibitor is a solid agent such as tablet and the content of the compound is usually preferably 0.1-10wt.% when the inhibitor is a liquid agent such as injection. Furthermore, the compound of the formula is preferably administered in a daily dose of 0.3-300mg/kg in the case of oral administration or 0.03-30mg/kg in the case of parenteral administration.
Postoperative delirium is one of the most prevalent postoperative complications, affecting mostly older adults. Its incidence is expected to rise because of surgical advances, shifting demographics, and increased life expectancy. Although an acute alteration in brain function, postoperative delirium is associated with adverse outcomes, including progressive cognitive decline and dementia, that place significant burdens on patients' lives and healthcare systems. This has prompted efforts to understand the mechanisms of postoperative delirium to provide effective prevention and treatment. There are multiple mechanisms involved in the etiology of postoperative delirium that share similarities with the physiological changes associated with the aging brain. In addition, older patients often have multiple comorbidities including increased cognitive impairment that is also implicated in the genesis of delirium. These tangled connections pinpointed a shift toward creation of a holistic model of the pathophysiology of postoperative delirium. Scientific advancements integrating clinical risk factors, possible postoperative delirium biomarkers, genetic features, digital platforms, and other biotechnical and information technological innovations, will become available in the near future. Advances in artificial intelligence, for example, will aggregate cognitive testing platforms with patient-specific postoperative delirium risk stratification studies, panels of serum and cerebrospinal fluid molecules, electroencephalogram signatures, and gut microbiome features, along with the integration of novel polygenetic variants of sleep and cognition. These advances will allow for the enrollment of high-risk patients into prevention programs and help uncover new pharmacologic targets.